BACKGROUND: Somatostatin is a pleiotropic peptide, exerting a variety of effects through its receptor subtypes. Recently, somatostatin has been shown to act as a chemoattractant for haematopoietic progenitor cells and hepatic oval cells (HOC) via receptor subtype 2 and subtype 4 (SSTR4) respectively. AIMS: We investigated the in vivo effect of somatostatin/SSTR4 on HOC migration in the injured liver model of rats and the type of signalling molecules associated with the chemotactic function. METHODS: Migration assay, HOC transplantation and phosphatidylinositol-3-kinase (PI3K) signalling were assessed with or without somatostatin and an analogue of somatostatin (TT232) that specifically binds to SSTR4. RESULTS: TT232 was shown to have an antimigratory action on HOC induced by somatostatin in vitro. In HOC transplantation experiments, a lower number of donor-derived cells were detected in TT232-treated animals, as compared with control animals. Activation of PI3K was observed in HOC exposed to somatostatin, and this activation was suppressed by either SSTR4 antibody or TT232-pretreatment. In addition, a PI3K inhibitor abrogated the motility of HOC. CONCLUSION: Together, these data suggest that somatostatin stimulates the migration of HOC within injured liver through SSTR4, and this action appears to be mediated by the PI3K pathway.
BACKGROUND:Somatostatin is a pleiotropic peptide, exerting a variety of effects through its receptor subtypes. Recently, somatostatin has been shown to act as a chemoattractant for haematopoietic progenitor cells and hepatic oval cells (HOC) via receptor subtype 2 and subtype 4 (SSTR4) respectively. AIMS: We investigated the in vivo effect of somatostatin/SSTR4 on HOC migration in the injured liver model of rats and the type of signalling molecules associated with the chemotactic function. METHODS: Migration assay, HOC transplantation and phosphatidylinositol-3-kinase (PI3K) signalling were assessed with or without somatostatin and an analogue of somatostatin (TT232) that specifically binds to SSTR4. RESULTS: TT232 was shown to have an antimigratory action on HOC induced by somatostatin in vitro. In HOC transplantation experiments, a lower number of donor-derived cells were detected in TT232-treated animals, as compared with control animals. Activation of PI3K was observed in HOC exposed to somatostatin, and this activation was suppressed by either SSTR4 antibody or TT232-pretreatment. In addition, a PI3K inhibitor abrogated the motility of HOC. CONCLUSION: Together, these data suggest that somatostatin stimulates the migration of HOC within injured liver through SSTR4, and this action appears to be mediated by the PI3K pathway.
Authors: Gisbert Weckbecker; Ian Lewis; Rainer Albert; Herbert A Schmid; Daniel Hoyer; Christian Bruns Journal: Nat Rev Drug Discov Date: 2003-12 Impact factor: 84.694
Authors: Rudolf Kirchmair; Margot Egger; Dirk H Walter; Wolfgang Eisterer; Andreas Niederwanger; Ewald Woell; Markus Nagl; Michael Pedrini; Toshinori Murayama; Silke Frauscher; Allison Hanley; Marcy Silver; Marianne Brodmann; Wolfgang Sturm; Reiner Fischer-Colbrie; Douglas W Losordo; Josef R Patsch; Peter Schratzberger Journal: Circulation Date: 2004-08-23 Impact factor: 29.690
Authors: Jan Best; Paul Manka; Wing-Kin Syn; Laurent Dollé; Leo A van Grunsven; Ali Canbay Journal: Hepatobiliary Surg Nutr Date: 2015-02 Impact factor: 7.293
Authors: Hong-Lei Weng; Xiaobo Cai; Xiaodong Yuan; Roman Liebe; Steven Dooley; Hai Li; Tai-Ling Wang Journal: Front Physiol Date: 2015-06-16 Impact factor: 4.566
Authors: Jan Best; Laurent Dollé; Paul Manka; Jason Coombes; Leo A van Grunsven; Wing-Kin Syn Journal: Front Physiol Date: 2013-09-26 Impact factor: 4.566